Sequence variations in the Epstein-Barr virus (EBV) latent membrane protein 1 gene have been described in numerous EBV-associated tumors with some of these variations, most notably a 30-base pair deletion in the cytoplasmic carboxylterminal domain, suggested as associated with an increase in tumorigenicity. In this study, EBV DNA sequence was determined from 92 tissue specimens or cell lines, including nasopharyngeal carcinoma, oral hairy leukoplakia, posttransplant lymphoma, post-transplant without pathology, mononucleosis, Burkitt's lymphoma, parotid tumor, and normal from distinct geographical regions. The amino-and carboxyl-terminal sequences and, in some cases, the full-length sequences of latent membrane protein 1 were determined. Characteristic sequence patterns distinguished strains, with the carboxylterminal sequence being the most informative in distinguishing among the strains. Phylogenetic relationships between strains were determined, as were signature amino acid changes that discriminate between them. A correlation between strain and disease or strain and geographic location was not detected. The sequence variation and signature sequences identified at least seven distinct strains, as well as hybrid strains that apparently result from recombination.
INTRODUCTION
The Epstein-Barr virus (EBV), a ubiquitous human herpesvirus, is associated with a variety of human neoplastic diseases, some with distinct geographical incidence. These neoplastic diseases include Burkitt's lymphoma (BL) endemic to equatorial Africa; nasopharyngeal carcinoma (NPC) common to southern China, Mediterranean Africa, and Inuit populations; and post-transplant lymphoma (PTL) and Hodgkin's lymphoma (reviewed in Raab-Traub, 1996) . EBV is also associated with the nonneoplastic diseases, infectious mononucleosis (Henle et al., 1968) and oral hairy leukoplakia (HLP) (Greenspan et al., 1985) .
The EBV-encoded latent membrane protein 1 (LMP1), considered the viral oncoprotein, is expressed in all of the above pathologies, with the exception of BL. LMP1 can transform rodent fibroblasts (Wang et al., 1985; Baichwal and Sugden, 1988; Moorthy and Thorley-Lawson, 1993) , can induce lymphoma and hyperplasia in transgenic mice (Kulwichit et al., 1998) , and is essential for EBV-mediated transformation of B lymphocytes (reviewed by Kieff, 1996) . Expression of LMP1 leads to induction of B cell activation antigens (Wang et al., 1988 (Wang et al., , 1990 , the expression of inhibitors of programmed cell death, bcl-2 and A20, (Henderson et al., 1991; Laherty et al., 1992) , and the induction of epidermal growth factor receptor expression and nuclear factor (NF)-B activation through the TRAF signaling pathway (Hammarskjold and Simurda, 1992; Mosialos et al., 1995) .
The LMP1 protein has a cytoplasmic amino-terminus, six transmembrane domains, and a long cytoplasmic carboxyl-terminal domain. LMP1 has considerable sequence heterogeneity among isolates, and potential strains have been defined by DNA sequence polymorphisms in both the amino-and carboxyl-termini within this gene (Miller et al., 1994; Sung et al., 1998) . These strains sort independently of the EBV types 1 and 2 that are distinguished by sequence divergence in the EBV nuclear antigens (EBNAs) (Adldinger et al., 1985; Sample et al., 1990) . Within LMP1, there is an 11-amino-acid repeat element of varying copy number, which has been shown to sort independently of the strain (Miller et al., 1994) , and a 30-base pair (bp) region that is consistently deleted in some strains of EBV. It has been suggested that some of the sequence variations within LMP1 represent mutational hotspots and that these changes and the 30-bp deletion may result in a more aggressive phenotype (Knecht et al., 1993; Kingma et al., 1996) . Other studies have observed that some variants are geographically restricted (Chang et al., 1995; Itakura et al., 1996; Leung et al., 1997) .
The present study was undertaken to identify se-quence patterns in both the amino-and carboxyl-termini of LMP1, determine signature amino acid changes that discriminate between the strains, and determine the relatedness between the strains using phylogenetic analysis. Using these discriminating features, the Classification and Regression Tree (CART) methodology (Breiman et al., 1984) was implemented to determine whether strain variation correlated with either disease state or geographic location.
RESULTS

Analysis of LMP1 amino-terminus and identification of distinct patterns
DNA sequences from EBV coordinates 169469-169222 from 77 tissue specimens or cell lines were compared with the B95-8 prototype sequence. Definite sequence patterns were identified, and the samples were grouped by these sequence patterns (Fig. 1 ). In keeping with the previous nomenclature, the strains are named after the geographic location where they were first isolated, even though the strains are not limited to that location. A strain identified from NPC specimens and previously designated, China 1 (Miller et al., 1994; Sung et al., 1998) , was found in 42 sequence samples, including those from NPCs 2, 3, 5, 10-13, 16, 17, 20-23, 26, 28, 33, 34, 36a, 36b, 37, 38a, 38b, 38c, 39-41, 43, 44, 46-52, 58, 59, 61, 62, 1510, and Cao and HLP 2a . In Ͼ80% of the isolates, this strain has bp changes at positions 169425, 169402, 169379, 169361, 169352, 169339, 169286, 169280, 169276, 169274, 169230, 169225 , and 169222, with less frequent changes (Ͼ54%) at bp 169467, 169437, and 169322 ( Fig. 1) . These bp changes in the China 1 strain lead to amino acid changes at positions 3 H3R (63%), 13 R3P (56%), 17 R3L (86%), 25 L3I (91%), 46 D3N (90%), 67 D3H (85%), 82 A3G (82%), 84 C3G (82%), and 85 I3L (81%). Silent changes are seen at amino acids 32 (91%), 38 (90%), 41 (83%), 51 (62%), 63 (83%), and 65 (82%) (Fig. 1) .
Six samples, NPC 1, 7, 19, 24, 27 , and 29a, represented the China 2 strain (Sung et al., 1998) , which includes changes at the following bp in over 83% of the isolates ( Fig. 1) : 169467, 169437, 169425, 169402, 169400, 169379, 169378, 169361, 169339, 169322, 169306, 169295, 169286, 169280, 169276, 169274, 169225, and 169222 . Less frequent changes (Ͼ67%) were detected at bp 169348 and 169230 (Fig. 1) . These changes lead to amino acid changes at positions 3 H3R (67%), 13 R3P (67%), 17 R3L (100%), 25 L3M (100%), 33 L3I (100%), 43 V3I (67%), 46 D3N (100%), 57 S3A (83%), 67 D3H (100%), 82 A3G (67%), 84 C3G (100%), and 85 I3L (100%).
Silent changes occur at amino acids 32 (100%), 38 (100%), 51 (100%), 60 (83%), 63 (100%), and 65 (100%). The China 2 strain shares many changes with the China 1 strain on the amino-terminus, but the methionine at position 25 and isoleucine at position 33 are unique to this strain and, as previously shown, perfectly discriminate between the China 1 and China 2 strains (Sung et al., 1998) .
Two samples, NPC 60 and Par 1 (parotid tumor), were of a third pattern, the Alaskan strain (Miller et al., 1994; Sung et al., 1998) , which includes bp changes at positions 169647, 169437, 169425, 169411, 169402, 169379, 169361, 169352, 169348, 169339, 169331, 169306, 169288, 169286, 169280, 169276, 169274, 169230, 169225, and 169222 (Fig. 1) . In the Alaskan strain, these bp changes lead to amino acid changes at positions 3 H3R, 13 R3P, 17 R3L, 22 S3P, 25 L3I, 43 V3I, 46 D3N, 57 S3A, 63 I3V, 67 D3H, 82 A3G, 84 C3G , and 85 I3L, with silent changes at amino acids 32, 38, 41, 48, and 65. The Alaskan strain also shares many changes with both the China 1 and China 2 strains, but the proline at position 22 and the valine at amino acid 63 are unique to this strain, and these two positions have been shown to discriminate this strain from the China 1 and China 2 strains (Sung et al., 1998) .
The Raji cell line and HLP 9 have multiple changes in common with the Alaskan strain with changes at 169467, 169466, 169402, 169379, 169348, 169306, 169288, 169286, and 169280 (Fig. 1) . These bp changes correspond to amino acid changes at positions 3 H3L, 25 L3I, 43 V3I, 57 S3A, and 63 I3V and silent changes at positions 32 and 65. Raji also has bp changes at 169469, 169339, and 169222 leading to amino acid changes of 2 E3D, 46 D3N, and 85 I3L. The Raji and HLP 9 samples have the valine at position 63 but lack the proline at position 22, changes that are characteristic of the Alaskan strain.
A pattern designated as the Mediterranean pattern, Med, was detected in 12 samples, including those from NPCs C15, 53, 54, and 57; cell lines AG876, P3HR1, and W91; Mono 1 (mononucleosis); BL 1; and PTL 2 and HLPs 10 and 11. This strain has few changes in the aminoterminus but is marked by bp changes at 169339 and 169222 (Fig. 1) . These bp changes result in amino acid changes at positions 46 D3N (40%) and 85 I3L (100%) (Fig. 1) . The leucine at position 85 is also found in the Alaskan, China 1, and China 2 strains, but the leucine at position 85 in the absence of the other multiple changes is indicative of the Med strain.
Two samples, PTL 1 and Mono 2, had a fifth pattern,
Sequence variation in the amino-terminal portion of LMP1. Numbers across the top row correspond to the EBV genome coordinates; names in the left column refer to the individual isolates. A plus sign indicates variation from the B95-8 prototype strain at this locus; a question mark indicates sequence beyond this point is unknown; and a dash indicates a deletion at this locus. The strain identifying changes are in bold, shaded, patterned, and arranged by groups.
the NC strain, which includes consistent bp changes at positions 169460, 169425, 169423, 169402, 169400, 169398, 169379, 169366, 169364, 169361, 169352, 169348, 169347, 169339, 169322, 169286, 169276, 169274, 169225, and 169222 (Fig. 1) . These bp changes result in amino acid changes at positions 17 R3L, 18 G3R or G3Q, 25 L3I, 26 G3I, 37 L3I, 43 V3T, 46 D3N, 67 D3H, 84 C3G, and 85 I3L . Silent changes are found at amino acids 5, 32, 38, 41, 51, and 63. The amino acid changes to isoleucine at position 37 and threonine at 43 are unique to this strain. Interestingly, this strain shares the change to an isoleucine at position 25 with the China 1 and Alaskan strains, but this change is due to an additional unique bp change at position 169400.
The remaining 13 isolates from NPCs 4, 6, 8, 9, 18, [30] [31] [32] 35, 42, 45, 55 , and 56 had few if any changes and were considered of the B95-8 pattern or strain (Fig. 1) .
Several of the sequence changes on the amino-terminus are shared among the different sequence patterns, but most are also marked by additional changes that are unique to each group (Fig. 1) .
Analysis of the LMP1 carboxyl-terminus and identification of strains
Eighty-three sequence samples from EBV coordinates 168755-168163 were obtained from 45 of the tissue specimens, and these were compared with the B95-8 prototype strain. Seven definitive patterns were identified (sequences not shown). The China 1 pattern (Miller et al., 1994; Sung et al., 1998) was detected in 24 samples, including NPCs 13, 17, 23, 31, 36a, 38a, 38b, 38c, 39, Cao, 1510; N 1a (normal) ; HLPs 1, 2a, 2b, 2c, 2d, 2e, 2f, 3a, 4a, 5a, and 9; with no posttransplant lymphoproliferative disease). The China 1 strain had 11 changes from B95-8, at positions 168687 G3A, 1688631 A3G, 168395 G3A, 168357 C3A, 168355 A3T, 168320 A3G, 168308 T3C, 168225 T3A , and the 30-bp deletion in Ͼ87% of the isolates, with less frequent changes (Ͼ52%) at bp 168694 T3C and 168295 A3T. These bp changes correspond to amino acid changes at positions 212 G3S, 309 S3N, 322 Q3N or Q3K, 334 Q3R, 338 L3S, and 366 S3T and the deletion of amino acids 343-352, with silent changes at amino acids 209, 230, and 342 (Fig. 2) . The amino acid changes at 212, 309, 322, 334, 338 , and 366 and the deletion of 343-352 were most strongly correlated (Ͼ87%) with this strain, with the asparagine at position 322 unique to this strain.
The China 2 pattern (Sung et al., 1998) was detected in 17 samples, including NPCs 1, 14, 15, 19, 24, 25, 27, 29a, 36b; HLPs 5c, 5d, 5e, 5f, 5g; and PTs 1d, 1e, and 1f C15, C17, C18, and C19; HLPs 2g, 3b, 3c, 5b, 6a, 6b, 6c, 7, and 11; N 1b and 1c;  and cell line W91. The Med strain had changes at 168395 G3A, 168357 C3G, 168266 A3G or the 30-bp deletion, and 168225 T3A or G in Ͼ88% of the isolates, with less frequent changes (Ͼ69%) at bp 168635 G3C, 168320 A3G, 168308 T3C, 168295 A3T, 168238 G3A or C. These bp changes correspond to amino acid changes at positions 229 S3T, 309 S3N, 322 Q3E, 334 Q3R, 338 L3S, 352 H3R or deleted, and 366 S3N or T or A, with silent changes at amino acids 342 and 361 (Fig. 2) . The amino acid changes at positions 229, 309, 322, 334, 338, 352 or deletion, and 366 delineated this strain, with the glutamic acid at 322 being unique to this strain.
Two samples, NPCs 16 and 29b, were very similar to the China 1 and Med strains. This China 3 strain had bp changes at positions 168694 T3C, 168687 G3A, 168631 A3G, 168308 T3C, 168295 A3T, the 30-bp deletion, and 168225 T3A. The corresponding amino acid changes were 212 G3S, 338 L3S, 366 S3T, and the deletion of 343-352 (Fig. 2) . Silent changes were found at amino acids 209, 230, and 342.
The Alaskan strain (Miller et al., 1994; Sung et al., 1998 ) was detected in three samples, including NPC 60, HLP 4b, and Par 1. This strain had changes at positions 168694 T3C, 168687 G3A, 168640 C3T, 168387 G3A, 168384 T3G, 168357 C3A, 168329 G3C, and the absence of the 30-bp deletion in all the isolates, with less frequent changes (Ͼ66%) at bp 168626 G3C, 168395 G3A, 168309 T3C, 168308 T3C, 168295 A3T, 168288 G3A, 168260 G3A, and 168257 G3T. These bp changes correspond to amino acid changes at positions FIG. 2. Amino acid variation in the carboxyl-terminal portion of LMP1. Numbers across the top correspond to the LMP1 amino acid positions under which the B95-8 prototype amino acid sequence is listed. The position of the 33-bp repeats is denoted across the top, names in the left column refer to the individual isolates, changes in the amino acids are denoted by the letter changes, a question mark indicates sequence beyond this point is unknown, and a dash indicates a deletion of this amino acid. The strain identifying changes are in bold, shaded, patterned, and arranged by groups.
212 G3S, 232 G3A, 309 S3N, 312 D3N, 313 S3A, 322 Q3K, 331 G3A, 338 L3P, 345 G3S, 354 G3D, and 355 G3V, with silent changes at 209, 227, and 342 (Fig. 2 ). The Alaskan strain had distinct changes from the other strains, notably the changes of amino acids to alanine at 232, asparagine at 312, alanine at 313, lysine at 322, alanine at 331, serine at 345, aspartic acid at 354, and valine at 355.
The sixth pattern, the NC strain, was detected in two samples: PTL 1 and Mono 2. This strain had consistent mutations at positions 168404 T3A, 168395 G3A, 168384 T3C, 168357 C3A, 168356 A3C, 168330 G3C, 168329 G3A, 168309 T3C, 168308 T3C, 168295 A3T, 168267 C3A, 168248 A3C, and the absence of the 30-bp deletion. These mutations resulted in amino acid changes at positions 306 L3Q, 309 S3N, 313 S3P, 322 Q3T, 331 G3Q, 338 L3P, 352 H3N, and 358 H3P with a silent change at 342 (Fig. 2 ). This strain also had distinct changes from the other strains with a glutamine found at amino acid position 306, a proline 313, a threonine 322, an asparagine at 352, and a proline at 358.
Another 13 samples had sequence nearly identical to that of the B95-8 strain. These included the cell lines Raji and P3HR1; PTs 1b, 1c, and 2; N 1d; and HLPs 2h, 3e, 3f, 8a, 8b, 8c, and 8d. These samples had sporadic bp changes, but consistent changes were not identified (Fig. 2) .
Several of the sequence samples, including those from Mono 1, AG876, HLP 3d, and HLP 4c, had sequence patterns suggestive of interstrain recombination and are discussed later.
Several of the bp changes were common to the different strains, including the silent change of a T3C at 168694 and a G3A at 168687 in the China 1, China 2, China 3, and Alaskan strains. The change of G3A at 168395, a T3C at 168308, and a T3A at 168225 was found in all strains with the exception of the B95-8 strain. Distinct changes in the glutamine at position 322 were identified in four of the strains, with an asparagine found in China 1, a glutamic acid in Med, a lysine in Alaskan, and a threonine in NC (Fig. 2 ). This amino acid change was fairly diagnostic of the strain.
Analysis of the full-length LMP1 and identification of strains
The sequence of both the amino and carboxyl domains was determined in 29 samples. The same strain was detected in the majority of these samples in both the amino-and carboxyl-termini. China 2 was identified in NPCs 1, 19, 24, 27, and 29a; China 1 in NPCs 13, 17, 23, 36a, 39, 1510 and Cao and HLP 2a ; the Med strain in NPC C15, HLP 11, and cell line W91; the NC strain in PTL 1 and Mono 2; and the Alaskan strain in NPC 60 and Par 1 (Fig.  3A) . NPCs 36a and 2a were the China 1 strain on the carboxyl-terminus, but because they lacked some of the characteristic changes in the amino-terminus, they were more distantly related (Fig. 3A) . Nine samples, Mono 1, Raji, AG876, P3HR1, NPC 16, NPC 31, NPC 36b, and NPC 56, and HLP 9, are discussed in the section on recombination.
Interstrain recombination
Several of the samples analyzed had amino acid changes characteristic of more than one strain. The 33-bp repeats in the carboxyl-terminus have been suggested as a site for recombination (Miller et al., 1994) . Analysis of the carboxyl-terminal sequence revealed that HLP 4c had the threonine at 229 characteristic of the Med strain on one side of the repeats and some of the Alaskan changes on the other side of the repeats, suggesting that this isolate was a product of interstrain recombination (Fig. 2) . This is particularly likely as this strain was identified in an HLP where lytic viral replication and recombination have been previously described and frequently occur . Similarly, HLP 3d had the characteristic threonine at 229 of the Med strain but was marked by the China 1 changes on the distal side of the repeats, in particular, the characteristic asparagine at amino acid 322 (Fig. 2) . In those samples with both amino-and carboxyl-terminal sequences, NPC 31 (Sung et al., 1998) resembles B95-8 in the amino-terminus and the China 1 in the carboxylterminus, suggesting that it also arose from recombination across the repeats (Fig. 3A) . Two samples, NPC 36a and NPC 36b, were identified in an NPC specimen that was clonal by the termini assay (data not shown) (RaabTraub and Flynn, 1986) . NPC 36a is China 1 in both the amino-and carboxyl-termini, whereas NPC 36b has China 1 characteristic changes in the amino-terminus with China 2 characteristic changes in the carboxylterminus distal to the 33-bp repeats (Fig. 3A) . This recombinant may have developed in the individual or may have been transmitted. NPC 56 appears to have resulted from a B95-8/Med strain recombination, whereas P3HR1
FIG. 3. Identification of strains of EBV by amino acid patterns in LMP1 and by phylogenetic analysis of LMP1 sequence. (A) Amino acid variation in the full-length LMP1. Numbers across the top correspond to the LMP1 amino acid positions under which the B95-8 prototype amino acid sequence is listed. The position of the 33-bp repeats is denoted across the top, names in the left column refer to individual isolates, changes in the amino acids are denoted by the letter changes, a question mark indicates sequence at this point is unknown, and a dash indicates a deletion of this amino acid. Strain identifying amino acid changes are in bold and characteristically shaded. Recombinant isolates can be identified by more than one strain identifying pattern and shading. (B) Phylogenetic tree drawn from the carboxyl-terminal nucleotide sequence of the samples using the site-dependent model with two parameters at each position (Felsenstein, 1995) and the neighbor-joining method (Saitou and Nei, 1987) . The isolates characteristically group according to strain, and the strains are denoted by shading with the recombinants denoted by double shading.
is a Med/B95-8 recombinant, and AG876 is a Med/China 1 strain recombinant (Fig. 3A) . NPC 16 had all the characteristic China 1 changes on the amino-terminus and the China 3 characteristic changes on the carboxylterminus, resulting in a recombinant strain, a China 1/China 3 strain (Fig. 3A) . The Raji cell line shares many of the Alaskan strain changes in the amino-terminus but resembles the B95-8 strain in the carboxyl-terminus, suggesting that it also arose from recombination (Fig. 3A) . HLP 9 appears to be an Alaskan/China 1 recombinant (Fig. 3A) . Mono 1 appears to be a double recombinant with Med characteristic changes in the amino-and distal carboxyl-termini and B95-8 characteristics in the intervening sequences resulting in a Med/B95-8/Med recombinant (Fig. 3A) .
Phylogenetic analysis of the viral nucleotide sequences
To strengthen the classification of the above patterns as true strains and to determine the phylogenetic relationships between the EBV isolates from the various disease states and geographic locations, the DNA sequences from the amino-terminus, carboxyl-terminus, and a fusion of the amino-and carboxyl-termini were analyzed. Distance matrices were calculated using the one-parameter model (Jukes and Cantor, 1969) , in which the rate of substitution is equal between all nucleotides; the Kimura (1983) two-parameter model, which assumes that transition-type changes are more likely to occur than transversion-type changes (in these isolates, this ratio is 1.3:1); and the model, which allows different Kimura parameters at each position (Felsenstein, 1995) . From these distances, phylogenetic trees were inferred using the neighbor-joining (Saitou and Nei, 1987) and UGMA (Nei, 1975) methods. The latter assumes a molecular clock (i.e., a constant rate of evolution among lineages). The tree presented (Fig. 3B) was reconstructed using the model that allows different parameters at each position and the neighbor-joining method, but all methods produced trees with similar branching patterns (data not shown).
The trees based on the amino-terminus did not clearly distinguish all the strains, but isolates of strains China 2, Alaskan, and NC were consistently grouped, suggesting that the distinguishing sequence patterns in these strains in the amino-terminus reflect their phylogenetic relationship (tree not shown). The variability in the China 1 strain made it difficult to form a single cluster.
The carboxyl-terminal sequences consistently produced trees of similar groupings, suggesting the strength of the changes in the carboxyl-terminus for classifying and distinguishing the strains. These trees revealed multiple branches with the seven identified sequence patterns usually clustering within a branch or between two closely related branches (Fig. 3B) . Several of the China 1 isolates, notably HLPs 1 and 9, PT 1a, N 1a, NPCs 36a, and NPC 1510 are positioned slightly away from the majority due to the absence of the silent change at amino acid 209 in HLP 1 and 9, PT 1a, and NPC 36a, and common T at position 192 in N 1a, NPC 36a, and NPC 1510 (Figs. 2 and 3B) . In all phylogenetic reconstructions, these samples consistently are grouped with the China 1 strain (data not shown). Also, HLP 5a, which has most of the China 1 changes, is positioned close to sister isolate HLP 5b due to the R shared at position 243 (Figs.  2 and 3B) . Several of the Med isolates, notably NPCs C15, C18, and C19, N 1c, and HLPs 3b, 3c, and 11, also cluster down from the majority of the Med isolates in the tree presented here due to the presence of the Gs in the repeat region (Figs. 2 and 3B ), but these samples also consistently grouped with the Med strain in all trees (data not shown).
These trees also reveal the degree of relatedness of the seven strains, with the China 1 and Med strains closely related and positioned off the same branch and the China 3 strain closely related to both these strains. The NC and Alaskan strains are closely related and somewhat related to the China 2 strain (Fig. 3B) . The trees derived from the full-length sequences showed the same consistent groupings and thus strengthen the classification of these patterns as true strains (tree not shown).
Classification of strains based on amino acid signature patterns
Because distinct sequence patterns (strains) were detected and the strains consistently grouped from the trees of the carboxyl-terminal sequence, the CART methodology was applied to determine the amino acid positions that could characterize them. Twenty-six samples over full-length sequence was analyzed (48 variable positions), 58 samples over the amino-terminus (16 variable positions), and 53 samples over the carboxyl-terminus (44 variable positions). Perfect discrimination between the strains was found only when the carboxyl-terminal sequences were analyzed and only for the phylogenetic tree groupings (strains), compared with disease or geographic location groupings.
The seven phylogenetically defined strains could be perfectly discriminated over seven loci in the carboxylterminus (Table 1) . A substitution of an aspartic acid for the glycine at amino acid 344 perfectly classifies the China 2 strain (Table 1 ). The China 1 strain can be classified by a serine at position 229, a substitution of an arginine for the glutamine at amino acid 334, and the deletion of 344 (Table 1 ). The Med strain can be discriminated from the other strains by the presence of a threonine at 229, a glutamic acid at 322, and either a glycine or the deletion of amino acid 344 (Table 1 ). The China 3 strain can be distinguished by a serine at 229, a glu-tamine at 322, a glutamine at 334, a serine at 338, and the deletion of amino acid 344 (Table 1 ). The Alaskan strain has a serine at 229, an asparagine at 312, a lysine at 322, a glutamine at 334, and a glycine at 344 (Table 1) . The NC strain can be classified by a serine at 229, a glutamine at 306, an aspartic acid at 312, threonine at 322, a glutamine at 334, and a glycine at 344 (Table 1) . These changes are all in comparison with the B95-8 prototype strain, and members of the B95-8 strain do not have changes at these seven loci (Table 1) . Additional amino acid changes occurred that were always present in some of the strains, in addition to the discriminating loci. The Alaskan strain is marked by an alanine at both 313 and 331. The NC strain has a proline at 313, an asparagine at 352, and a proline at amino acid 358. When the discriminating amino acid 344 was deleted from the isolates and the CART analysis redone, perfect discrimination between the seven strains was still seen over six loci, amino acid positions 306, 312, 322, 331, 334, and 338, further supporting the designation of the above seven sequence patterns as true strains.
When the CART methodology was applied with the samples grouped by disease or geographic location, perfect discrimination was not found. This indicates that strains or specific amino acid changes did not perfectly correlate to a specific disease state or geographic location. However, some strains, as determined by the carboxyl-terminal sequence only, were more prevalent in certain populations. In the Asian samples, 63% were China 1, 12% were China 2, 3% were China 3, and 17% were B95-8 strains. Among the Mediterranean and African samples, 90% were Med and 10% were B95-8. The U.S. samples were 23% China 1, 12% China 2, 31% Med, 4% Alaskan, 8% NC, and 23% B95-8 strains. Both Alaskan samples were the Alaskan strain, and the sole European sample belonged to the B95-8 strain.
Error rate of viral DNA polymerase versus host DNA polymerase
In latent infection, the EBV genome is replicated by the host DNA polymerase, whereas in permissive infection, EBV DNA is replicated by the viral DNA polymerase. HLP is the only example of a permissive EBV infection and is responsive to inhibitors of the viral DNA polymerase, such as acyclovir . Several of the strains were found in examples of latent (NPC, N, PT, and BL) and permissive (HLP) infection. This finding allows for a comparison of the relative error rate of the host and viral polymerases. The error rate of Taq polymerase is ϳ0.001% (Eckert and Kunkel, 1990 ) and therefore did not significantly affect the analysis of the data. By analyzing the 592 nucleotides within the carboxyl-terminal sequence, the mean error rate was calculated for each polymerase by totaling the number of changes outside the signature from all representatives of either latent or permissive infection of a given strain and dividing by the total number of nucleotides. In the case of more than one sample of the same strain from a given specimen, the sample with the greatest number of changes outside the signature was used. This relative rate does not reflect the actual error rate of the polymerases, as the bp changes represent the accumulated changes after multiple cycles of replication, and other viral or cellular proteins may contribute to replication fidelity. A total of nine samples of the China 1 strain were obtained from latent infections, where the viral genome is replicated by the host polymerase, and had an estimated error rate of 0.64%. The five China 1 samples from permissive infections had an error rate of 0.71% (Table 2 ). In the China 2 strain, the host polymerase had an error rate of 0.64%, and the viral polymerase had an error rate of 0.68% (Table 2 ). Similar error rates between the host and viral polymerases were also identified in the Med strain with rates of 1.08% and 0.98%, respectively ( Table 2 ). The B95-8 strain had the greatest difference in the error rates, with the viral polymerase error rate of 1.2% and the host polymerase error rate of 0.71% (Table 2) . To compare the error rate of host versus viral polymerase, a binomial test for the difference in proportion was used.
The P values were generated for each strain, comparing the proportion of changes outside the signature for latent infection against that for permissive infection. All strains had a value of P Ͼ 0.05, indicating no significant difference between the error rates during latent or permissive infection.
DISCUSSION
In this study, the DNA sequence variation in LMP1 of EBV isolates was analyzed and strains were identified based on these sequence patterns and on the phylogenetic trees. EBV strains have been previously distinguished by loss of XhoI cut site (Abdel-Hamid et al., 1992) , the presence of a 30-bp deletion, and sequence variation in the amino-terminus of LMP1 (Miller et al., 1994; Sung et al., 1998) . The data presented here indicate that these changes do not perfectly discriminate between the strains. The China 1, China 3, and Med strains all have the deletion, whereas China 1, China 2, Alaskan, and NC strains all have lost the XhoI cut site. However, the unique and numerous changes in the amino-terminus of the China 2, Alaskan, and NC strains do consistently group in the phylogenetic analysis, supporting their classification as strains. The China 1 strain had the greatest variability in the amino-terminus but was consistently marked by the change of a leucine to isoleucine at amino acid position 25, as previously noted (Sung et al., 1998) .
The carboxyl-terminal sequence of LMP1 distinguished seven distinct sequence patterns or strains. These seven strains consistently associated in all trees, strengthening their classification as true strains. These strains can be perfectly discriminated over seven loci, at amino acids 229, 306, 312, 322, 334, 338, and 344 . The change at amino acid 322 is particularly informative with an asparagine present in China 1, a glutamic acid in Med, a lysine in Alaskan, a threonine in NC, and a glutamine in B95-8, China 2, or China 3 strains. A similar analysis of newly discovered Kaposi sarcoma-associated herpesvirus revealed that there were three distinct strains marked by signature bp changes (Zong et al., 1997) .
Two NF-B-activating regions have been identified within the carboxyl-terminus of LMP1 (Huen et al., 1995) located at amino acid positions 187-231, CTAR1, and 351-386, CTAR2. A conservative change occurs in CTAR1 with the change of the serine to threonine in the Med and China 2 strains at amino acid 229. An additional change occurs in CTAR1 with the change from a glycine to a serine in amino acid 212 in the China 1, China 3, China 2, and Alaskan strains. Nonconservative changes were also identified in several isolates. Three China 2 isolates have a glutamine, and Raji and HLP 1 have an asparagine in place of the histidine at amino acid 213. Raji, W91, and HLP 1 have a glutamine replacing a glutamic acid at position 214. Five China 2 isolates have a glycine instead of an arginine at amino acid 223. Raji and NPC 29 also have a leucine in place of histidine at amino acid 225. In the distal region, CTAR2, all strains with the exception of B95-8 show the conservative change of a serine to threonine or alanine at amino acid 366. The NC strain shows nonconservative changes at amino acid 352, a histidine to asparagine, and amino acid 358, a histidine to proline. The Alaskan strain has nonconservative changes at amino acids 354, glycine to aspartic acid, and 355, glycine to valine. In 12 of 17 China 2 isolates, a nonconservative change at position 355 is seen: glycine to alanine or threonine.
Within the two NF-B-activating domains, two critical motifs have been identified that bind the tumor necrosis receptor-associated factors, TRAF and TRADD. The PX-QXT motif at amino acids 204-208, which directly binds the TRAFs 1, 2, 3, and 5 (Mosialos et al., 1995) and induces epidermal growth factor receptor expression (Miller et al., 1997) , is unchanged in all 84 isolates except HLP 3e, which has amino acid 207 changed from an alanine to a valine. Also, the PXQXS motif at amino acids 379-383, which binds the TRADD adapter protein, is conserved in all isolates, further strengthening the importance of TRAF signaling to LMP1 function. Interestingly, an additional PXQXT motif at amino acids 320-324, outside CTAR1 and CTAR2, is altered in the China 1, Med, Alaskan, and NC strains with mutation of the critical Q at 322, suggesting that this motif is not essential to LMP1 function. The LMP1 sequences in both the baboon and rhesus EBV-related lymphotropic herpesviruses are quite divergent from EBV LMP1 but retain homologous TRAFinteracting regions. Rhesus EBV contains five potential TRAF-binding motifs, although it is unknown whether all of them are essential for LMP1 function (Franken et al., 1996) . In EBV LMP1, the PHDPLP motif located from amino acids 302-307 has been suggested to bind the JAK 3 kinase (Gires et al., submitted for publication) and is conserved in five of the strains; however, the amino acid 306 is changed to a proline in the Alaskan strain and to a glutamine in the NC strain. It is unknown whether these mutations would affect the activation of the JAK/ STAT pathway. The 30-bp deletion of amino acids 343-352 has been proposed to occur during replication through homologous recombination between duplicated sequences, bp 168256-168265 and bp 168295-168286, which flank the deleted region (Sandvej et al., 1994; Sung et al., 1998) . In some of the samples of the China 1, Med, and China 3 strains, the repeat region is extended by the change of an A to a T at 168295, possibly facilitating the deletion of the sequences (Sung et al., 1998) . However, a parental form of the China 1 strain, lacking the 30-bp deletion, was not identified, suggesting that the deleted form has completely replaced the putative original strain. Only in the Med strain were both deleted and undeleted forms detected, suggesting that the deletion does develop from an undeleted parental strain. A recent study that used LMP1 sequence variation to track EBV strain prevalence in long-term HIV infection did identify isolates that appeared to be China 1 strains that were undeleted (Berger et al., 1999) . This study found no correlation between the presence of the 30-bp deletion and the development of AIDS-NHL. The China 2 strain has changes at bp 168290 and 168257 within these duplicated sequences, which apparently hinder recombination, hence preventing the deletion of the intervening 30 bp (Sung et al., 1998) . The Alaskan strain has changes at 168288 and 168260 that also disrupt the homology and inhibit the deletion. The previously described isolate with the 69-bp deletion (Larcher et al., 1997) does not have homologous sequences flanking the deletion, so it is uncertain how this deletion occurred.
The large number of samples representing both latent and permissive infection also allowed for the comparison of host and viral polymerase error rates. The calculated error rate, based on changes outside of the signature amino acid changes, suggests that the EBV DNA polymerase has fidelity comparable to that of the host DNA polymerase. The fact that the viral polymerase can maintain DNA fidelity in HLP with its fulminant lytic viral replication is noteworthy. The high fidelity of the viral polymerase is also indicated by the remarkable conservation of the signature amino acids that distinguish the strains and the rare occurrence of additional bp changes within strains. Similarly, with each of the Kaposi sarcoma-associated herpesvirus strains, there are very few bp changes outside the signature sequences (Zong et al., 1997) .
Interstrain recombination in the EBNA2 gene has been identified in EBV isolates from the permissive infection in HLP . The carboxyl-terminus of LMP1 contains an 11-amino-acid repeat region, codons 250-308, of varying copy number through which interstrain recombination could occur (Miller et al., 1994) . The identification of multiple EBV strains suggests that some isolates have arisen from recombination. Eleven samples identified in this study appear to result from recombination, seven of which may have occurred from recombination across the repeat region: HLP 4c, HLP 3d, HLP 9, NPC 31, NPC 36b, NPC 16, P3HR1, and AG876. Interestingly, NPC 36a and 36b have the same aminoterminal sequence but distinct carboxyl sequences. The other three samples, Mono 1, NPC 56, and Raji, apparently result from recombination outside of the repeat region, confirming a previous suggestion that recombination can occur within unique sequences (Sung et al., 1998) .
Importantly, these same seven strains can be identified in most of the published sequences of additional isolates. However, it is likely that this is an underrepresentation of the possible LMP1 sequences and that other strains exist. A recent study of EBV strain variation in HLP identified multiple potential substrains and novel recombinant strains (Walling, et al., 1999) . The only strain previously described but not identified in this study was a strain with a 69-bp deletion (Larcher, et al., 1997) . This larger deletion seems to have occurred in a Med strain because it has the characteristic threonine at 229. The fact that the China 3 strain was detected in only two isolates in this study suggests that it may represent a very rare strain or may be a possible double recombinant, a China 1/B95-8/China 1 strain, notably because the single China 3 isolate with full-length sequence, NPC 16, had all the characteristic China 1 changes on the amino-terminus. Based on the carboxyl-terminal sequence patterns, the China 1 strain appears to be the most prevalent and is detected in both normal tissues and pathologies in Europe, America, and Asia (Table 3A) . Among European isolates, the China 1, Med, B95-8, and NC strains were identified in normal tissue specimens; B95-8, NC, Med, and China 1 strains were identified in Hodgkin's disease specimens; isolates from infectious mononucleosis were B95-8, NC, China 1, or Med strains; peripheral T cell lymphoma specimens had B95-8, Med, or China 1 strains; lymphoproliferative disease specimens had China 1, B95-8, or Med strains; tonsillar hyperplasia specimens had B95-8 or China 1 strains, and angioimmunoblastic lymphadenopathy specimens had China 1 or Med strains (Knecht et al., 1993 (Knecht et al., , 1995a Sandvej et al., 1994 Sandvej et al., , 1997 Berger et al., 1997) . Among Americans, infectious mononucleosis specimens could be categorized as having B95-8, Med, China 1, or China 2 strains; HLP as having China 1; and post-transplant lymphoproliferative disease specimens as having China 1, B95-8, Med, or NC strains (Palefsky et al., 1996; Smir et al., 1996; Berger et al., 1997) . Among Asian isolates, the China 1 and B95-8 strains were found in normal specimens; the China 1, China 2, and B95-8 strains in infectious mononucleosis specimens; the China 1 and China 2 strains in chronic EBV specimens; the China 1 and China 2 strains in carcinomas; the China 1, China 2, and Med strains in lymphomas; the China 1 and China 2 strains in gastric tumors; the China 1 and China 2 strains in NPC; and the China 1 and B95-8 strains in peripheral T cell lymphomas (Sandvej et al., 1994; Chang et al., 1995; Cheung et al., 1996; Itakura et al., 1996; Leung et al., 1997) . Table 3B shows the combined incidence of the strains (based solely on the carboxyl-terminal sequence) in the various disease states from the data presented in this study and the others previously cited. Although it is unclear in this survey whether the disease distribution of the strains corresponds to the geographic prevalence of that strain in that population, all strains have pathological potential (Tables 3A and 3B ). In some instances, one strain appears to be more prevalent in a disease than in the normal population, and an exact test for independence between strains and diseases was performed and P values calculated using a Monte-Carlo procedure for the Asian, European, and U.S. isolates. In these three cases, a significant correlation between disease and strain was not found, as the calculated P values were Ͼ0.05 (data not shown). However, these suggestions will have to be further investigated due to the nonrandom sampling and the low number of normal samples in this analysis.
The identification of strains also allows for the identification of samples that contain more than one strain. HLPs have been shown to harbor more than one strain through EBNA typing and recently through analysis of the LMP1 sequence (Walling et al., 1999) . HLP 2 and HLP 3 contain China 1, Med, and B95-8 strains. HLP 4 contains China 1, Alaskan, and Med/Al strains. The presence of the recombinant strain Med/Al could indicate that in this HLP, a Med strain was present that was not captured for analysis. HLP 5 has China 1, Med, and China 2 strains. Interestingly, three strains, China 1, B95-8, and Med, were detected in N 1 from a normal lymph node, indicating that normal hosts also can be infected with multiple strains. PT 1 also harbors three strains, China 1, B95-8, and China 2. This finding may be due to strains acquired via transfusions either preceding or following transplantation. Two NPCs, 29 and 36, of 62 had two strains of EBV. Clonal EBV was detected in NPC 36, suggesting that either the progenitor cell was simultaneously infected by two strains that formed episomes containing identical number of terminal repeat elements or one strain represents a strain found in infiltrating lymphocytes. The clonality of NPC 29 is unknown, so it could be a rare biclonal NPC, or the presence of two strains could also result from one strain in tumor tissue and the other from infiltrating lymphocytes (Sung et al., 1998) .
Previous analyses of the relative prevalence and studies of transmission have been dependent on identification of type 1 or type 2 EBNA2 and EBNA3 sequences (Gratama et al., 1990; Lung et al., 1991; Alfieri et al., 1996) . Previous studies have revealed that the sequence variations of LMP1 do not cosegregate with EBV type, although China 1 LMP1 has been more frequently detected in type 1 EBV, and China 2 and Alaskan LMP1 have been more frequently detected in type 2 EBV (Abdel-Hamid et al., 1992; Sung et al., 1998; Cheung et al., 1998) . The lack of correlation between EBNA2 and LMP1 variants may also reflect recombination that has occurred. The identification of sequence changes in LMP1 that clearly distinguish seven strains of EBV will enable a more accu- Note. Geographic distribution of the seven EBV strains (as determined by the C-terminal sequence) combining the data in this study (78 samples) and others cited in the discussion (423 published samples that were assigned one of the seven strains based on sequence changes in the Cterminus).
rate study of transmission and facilitate the detection of possible strain prevalence in distinct infections.
MATERIALS AND METHODS
Tumor samples and cell lines
The 92 EBV-positive specimens included the following: NPCs 1-15 were from northeastern China (nonendemic region); NPCs 16-34, 61, 62, and NPC Cao were from southern China (endemic region); NPCs 35-47 were from Malaysia, but of Chinese origin; NPCs 48-52 were Malaysian in origin; NPC 1510 was from Taiwan; NPCs 53-56 as well as NPCs C15, C17, C18, and C19 were Mediterranean in origin; NPC 57-59 were American in origin; NPC 60 as well as Par 1 were Alaskan in origin; HLP 8 was from Scotland; HLPs 1-7, 9-11, PTL 1-2, PT 1-2, N 1, Mono 1-2, BL 1, and B lymphoid cell line B95-8 (mononucleosis) were American in origin; and B lymphoid cell lines AG876, Raji, W91, and P3HR1 (Burkitt's lymphomas) were African in origin. Viral replication in HLP was confirmed by the identifi- Note. Disease distribution of the seven EBV strains as determined by the C-terminal sequence combining the data in this study (78 samples) and others cited in the discussion (423 samples).
cation of the EBV termini (Gilligan, et al., 1990) . Lowercase letters following the sample number denote the recovery of more than one isolate from the same sample.
The LMP1 sequence of the following samples has been previously described: NPCs 1-15, 18-29, and 31-33 (Sung et al., 1998); NPCs 16-17, 34-35, 53-60, C15 , C17, Par 1, PTLs 1-2, W91, and P3HR1 (Miller et al., 1994 (Miller et al., , 1998 ; NPC Cao (Hu et al., 1991) ; NPC 1510 ; B95-8 (Baer et al., 1984) ; AG876 (Sample et al., 1994) ; Raji (Hatful et al., 1988) ; and HLPs 1-8 and Mono 1 (Walling et al., 1999) .
Tumor processing and isolation of genomic DNA Frozen tumors were processed as described previously (Raab-Traub et al., 1983) . Tumor specimens were pulverized in a microdismembrator and suspended in 4 M guanidine isothiocyanate (GITC). Peripheral blood lymphocytes were purified over lymphocyte separation media (Organon Teknika, Durham, NC), washed, and resuspended in GITC. After centrifugation through a cesium chloride step gradient, the DNA was dialyzed, digested with proteinase K, and phenol-chloroform extracted. Paraffin-embedded samples were extracted twice with octane, washed twice with absolute ethanol, proteinase K digested, and heated to 95°C for 10 min.
DNA sequencing
The DNA sequence corresponding to LMP1 was determined by first amplifying 0.3 g of tumor DNA with the polymerase chain reaction (PCR) using Taq polymerase (Promega, Madison, WI), vent polymerase (New England Biolabs, Beverly, MA), or Expand High Fidelity PCR System (Boehringer Mannhein, Indianapolis, IN). The aminoterminal portion of LMP1 from 77 tissue specimens or cell lines was amplified using primers LMP9233 and LMP9600A, LMP FUE and FUB, or LMP FUE and 168808 (Table 4) , followed by asymmetric amplification and dideoxy sequencing using the same primers as previously described (Miller et al., 1994) . The carboxyl-terminal portion of LMP1 was determined in 45 specimens by first amplifying with primers LMP3UT and 168808 (Table  4 ). This product was Qiaquick (Qiagen, Studio City, CA) purified, and dideoxy sequenced with the same primers. For those samples where we were able to amplify the full-length LMP1 sequence, the DNA was first amplified with primers LMP3UT and LMPEco (Table 4 ). This product was Qiaquick purified, restriction digested with EcoRI and HindIII, and cloned into pGem3Z (Promega). Plasmid DNA from individual clones was sequenced using the dideoxynucleotide chain termination method (Sequenase; Amersham, Arlington Heights, IL) and primers LMPFUE, LMPIN, 168808, FUBR, LMP3UT, and LMPEco (Table 4) . Of the 23 samples cloned, 14 had more than one clone sequenced to confirm the sequence data. Previously published samples NPCs 16, 59, and 60 and PTLs 1 and 2 were further analyzed for the complete carboxyl-terminal region by amplification with primers Rep5 and LMP3UT followed by asymmetric PCR and sequencing using the same primers (Table 4) . Some of the samples were sequenced at the University of North Carolina-Chapel Hill Automated DNA Sequencing Facility on a model 377 DNA Sequencer (Applied Biosystems Division, Perkin-Elmer Cetus, Norwalk, CT) using the ABI PRISM Dye Terminator Cycle Sequencing Ready Reaction Kit with AmpliTaq DNA Polymerase, FS (Applied Biosystems Division, Perkin-Elmer Cetus.
Phylogenetic and CART analyses
To determine the phylogenetic relationships within the various EBV sequence samples representing various disease states and from the various geographical regions, the LMP1 sequence, including codons 1-70 and 192-386, was compiled from the 92 specimens. Sequences were aligned and distance matrices were calculated with the PHYLIP DNADIST program (Felsenstein, 1995) , using the Jukes-Cantor (1969) , Kimura (1983) twoparameter model with a transition/transversion ratio fixed at 2 and a site-dependent model with two parameters at each position (Felsenstein, 1995) . Phylogenetic trees were constructed from these distance matrices by both the neighbor-joining (Saitou and Nei, 1987) and UPGMA, average linkage clustering (Nei, 1975) , methods, using the NEIGHBOR and DRAWTREE programs from the PHYLIP package (Felsenstein, 1995) . CART methodology (Breiman et al., 1984) was used to construct classification trees to determine amino acid positions that are predictive of a particular grouping using the sequence from the 92 tissue specimens or cell lines described above. For the amino-terminal region, 58 sequence samples were analyzed over 16 amino acid positions, which included only those loci at which an amino acid change had occurred in more than one isolate. For the carboxyl-terminal region, 53 sequence samples were analyzed over 44 positions, and for full-length analysis, 26 sequence samples were analyzed over 48 positions. Any duplicates of the same strain from the same tissue were eliminated. The CART analysis was performed with the isolates grouped by disease, geographical region, and phylogenetic relationships.
Calculation and statistical analysis of error rates of host and viral polymerases
To calculate the error rate of the host and viral polymerases, the samples were divided into latent infection, which included isolates from NPC, N, PT, and BL, or permissive infection, which included isolates from HLP, to represent host or viral polymerase. The carboxyl-terminal sequence, which covered 592 nucleotides per sample, was used. For each strain, the total number of changes outside the signature were compared with the total number of nucleotides, and in the case of more than one sample of the same strain from a given specimen, the sample with the most changes outside the signature was used. From this total number of changes outside the signature and the total number of nucleotides, a mean percent error was calculated for the different polymerases. To determine whether the difference in error rates was significant between the two polymerases, the data were analyzed using a binomial test for the difference in proportions. P values were generated via a binomial test comparing the proportion of changes outside the signature for latent infection with that for permissive infection for each strain.
